Telemedicine & Initiating Buprenorphine Treatment

Telemedicine & Initiating Buprenorphine Treatment

This report concludes that DEA and SAMHSA have the legal authority to extend the flexibilities granted during the COVID-19 public health emergency without additional authorization from Congress. DEA and SAMHSA have the authority to jointly issue regulations allowing practitioners to prescribe buprenorphine without first conducting an in-person medical evaluation. As an alternative, DEA can use its authority to establish a special registration for telemedicine program while SAMHSA issues an associated policy. As another alternative, SAMHSA and DEA can use the opioid-specific public health emergency declaration to offer a longer term, but not permanent, option to extend these flexibilities.

Bridget C.E. Dooling and Laura E. Stanley

Regulatory Studies Center

23 February 2021

I didn't find this helpful.This was helpful. Please let us know if you found this article helpful.
By |2021-03-11T14:45:02-08:00January 1st, 2018|Medical, Occupational Licensing, Reference, Reforms|